TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Child healthy eating behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of unintended pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change in eczema area and severity index (EASI) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in development quotient (DQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Free of Respiratory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Occurrences of Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose of PXD101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: down-regulation of thymidylate synthase in patient tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Wong-Baker FACES Pain Scale-Revised (FPSR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Doppler Ultrasound measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vision Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brief Michigan Hand Questionnaire Score Difference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum Etonogestrel Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change From Baseline in Health Related Quality of Life (HRQoL) Using SGRQ Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma concentration of darexaban and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EEG power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with no mistakes from diagnosis to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratotic nodular size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Metabolic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of transplantation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of Orthopaedic Trauma Open Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sense of security regarding drug treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with drug counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parents' experience with phototherapy treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to Erbitux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Late lumen loss of vessel segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in 2h-postprandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Response Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with reported adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with stable microbiome engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHEA levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post operative knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parenting behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child disruptive behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Eructation/Sour Eructation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Painful Swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Elevation in serum IRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a CDAI score of < 150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baby's pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baby's heart beat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: baby's blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: baby's body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baby's SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of composite of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean protein intake per kg of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Completing Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: minute ventilation (MV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rapid shallow breathing index (RSBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in tissue perfusion (regional tissue oxygen saturation (StO2%))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence and nature of fibrosis and/or lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POSAS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes from baseline pain sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pelvic inflammatory disease
Endpoint domain: Adverse events/effects
Primary endpoint: Renal response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in hair cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response in negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Global-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IHT Blood Test Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of TNF-alpha antibodies in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evaluation of the quality of healthcare delivery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in self-reported adherence to medicines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of symptoms of depression and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Direct observation of procedural skills (DOPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUC(0-inf)) of Guaifenesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to a major wound complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of dose limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events reports
Endpoint domain: Adverse events/effects
Primary endpoint: Pain assessed by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 425809 in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Donepezil in Plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 425809 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Donepezil in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Venous Thromboembolic Events (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural/Device related serious adverse events at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic functional improvement at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with suspected acute coronary syndrome admitted to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cognitive function in healthy individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive function in patients with first episode depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive function in healthy individuals after cerebellar electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful First Attempt Peripheral Venous Cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Completed PT Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Seated SBP at office
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bonding Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with proven eradication of helicobacter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of transfer to inpatient ward
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Forced Expiratory Volume in 1 seconds (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy Assessment through Ultrasound Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Idiopathic Normal Pressure Hydrocephalus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in antibody titers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Participants Who Met Remission
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: breath F13CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological evidence of correction of graft skin architecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: compliance to nutrition therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients Who Received Preferred Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lapatinib Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Lapatinib Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Lapatinib Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of treatment on muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of acute toxicity in radiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with EMR related pain post-procedurally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thickness of levator ani
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Size of levator hiatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients Who Developed Post-ERCP Pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Repeatability and reproducibility of the result in controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of antiplatelet or von Willebrand factor deficiency/major constitutional thrombopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Subjective Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cough suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lateralization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Reception Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug penetration of the blood brain barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSF pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diurnal Intraocular Pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in HbA1c value from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of device related serious adverse events requiring an early removal
Endpoint domain: Adverse events/effects
Primary endpoint: Force of contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the size of the functional, latent HIV-1 reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of viral rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to return of HIV-1 viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Responding to Treatment: All Treated Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count: All Treated Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastroenteritis symptoms duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discrimination capacity of v-MUCP for the diagnosis of SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune Reconstitution at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune Reconstitution at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neointima hyperplasia volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Hepatic Venous Pressure Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Safety of ingenol derivative
Endpoint domain: Adverse events/effects
Primary endpoint: Parameters at which UPT terminates VT and VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: B-hydroxybutyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acetoacetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fugl-Meyer Upper Extremity scale (F-M UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Electrocardiogram Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving a ≥5-point increase in MSQ-RFR and MSQ-RFP domains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients achieving a ≥8-point increase in MSQ-EF domain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Evolution of the score of theory of mind
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Total Score of Gross Motor Function Measure (GMFM-88)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle Tone Assessed by Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC(0-16)) of Endogenous Glucose Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of neovascular membrane associated with AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of aHUS relapse
Endpoint domain: Mortality/survival
Primary endpoint: Maximum-tolerated dose (MTD) of DTP348
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful enrollment of patient-caregiver dyads
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful completion of patient-caregiver dyad data collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient expectation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted Geometric Mean Maximum Drug Concentration (Cmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Geometric Mean Area Under the Concentration Time Curve (AUC) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clusters of clinical symptoms in Functional GI disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Episodic score recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distance between papilla tip and contact point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Component Summary (PCS) of SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Variation in cardiopulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the OB/GYN Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the Primary Care Physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Musculoskeletal Tumor Society score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean maximum flexion of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: The six degrees of freedom of the gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Executive Language Functions (Category Verbal Fluency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social skills improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Saturation measurement agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute urinary and rectal toxicities
Endpoint domain: Adverse events/effects